Compare ING Groep NV (ING) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs Organon & Co. Common Stock — how do they compare? ING Groep NV trades at $33.42 (market cap $94.92B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: ING Groep NV is far larger — about 26.2× Organon & Co. Common Stock's market cap, and ING Groep NV pays the higher dividend (3.93%). Which is the better fit depends on your goals — on Pluang, investors hold ING Groep NV for 94 Days and Organon & Co. Common Stock for 0 Days on average.
| ING | OGN | |
|---|---|---|
Market Cap | $94.92B | $3.62B |
Volume | 2,055,666 | 2,892,999 |
Sector | Financials | Health |
52-Week High | $37.27 | $13.81 |
52-Week Low | $23.66 | $5.70 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $237.77B | $11.04B |
Dividend Yield | 3.93% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING trades at $33.46, up 0.21% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.79 exceeding the $0.75 estimate. Revenue reached $22.90 billion in 2025, with a net income margin of 28.34%. Analyst sentiment is positive, with 11 buy ratings and no sell ratings among 17 analysts. Recent news highlights an upgraded ROE target above 16% for 2027 and strategic focus on organic growth.
The outlook for ING is cautiously optimistic, supported by earnings momentum and favorable analyst coverage. Key opportunities include revenue growth and profitability targets, while risks involve persistent negative operating cash flows and regulatory scrutiny, such as recent capital requirements in Australia. The stock's valuation metrics, including a P/E of 12.99, suggest reasonable pricing relative to earnings.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
